Skip to content

Oncotelic Therapeutics

6 viewers · 30d

Total raised

$987K

+$712K this year

2 filings since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $712K
ROUNDS
2
INVESTORS
4
FOUNDED
N/A
HQ
Agoura Hills, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

Oncotelic Therapeutics, Inc. is a publicly traded, clinical-stage biotechnology company developing RNA therapeutics and small-molecule drugs for immuno-oncology and virology. The company's primary focus is on advancing its lead candidate, OT-101, which targets the TGF-β pathway to treat solid tumors and severe viral diseases. Oncotelic also leverages a proprietary AI platform to support its research and development efforts.

What sets it apart

The company's strategy integrates a first-in-class TGF-β antisense RNA therapeutic (OT-101) with an AI-augmented research platform (PDAOAI) to accelerate the development of precision oncology treatments.

Funding history

2 rounds
Equity+2Jul 10, 2026
Form D
+$712K$987K total
Equity+2Dec 4, 2025 · $25K min
Form D
+$275K$275K total

Products

1 tracked

OT-101 (TGF-β antisense)

RNA Therapeutic

OT-101 is a lead clinical-stage antisense RNA therapeutic that targets and inhibits the production of TGF-β2, a cytokine that suppresses the immune system within the tumor microenvironment. Initially developed for solid tumors like high-grade glioma, it is also being investigated as a host-directed therapy for severe viral infections, including COVID-19, by modulating a patient's immune response to the pathogen.

  • Antisense RNA mechanism specifically targeting TGF-β2.
  • Designed to reactivate anti-tumor immunity by relieving immune suppression.
  • Potential application in both oncology as a monotherapy or combination agent and in virology as a host-directed therapy.

Links

WebsiteLinkedInSEC EDGAR filings